Please provide your email address to receive an email when new articles are posted on . A larger lung function improvement was not seen with vs. without antibiotic changes in pulmonary exacerbation ...

Please provide your email address to receive an email when new articles are posted on . Percent predicted FEV 1 did not improve after systemic corticosteroid treatment. This treatment was also not ...

For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a study published in the April 24 issue of the New England Journal of Medicine.

In patients with cystic fibrosis (CF), the occurrence of pulmonary exacerbations requiring intensive therapy (PERITs) was associated with marked decline in lung function that was not always reversed ...

Researchers have found in a new study that the hemoglobin, albumin, lymphocyte, and platelet score serves as an independent predictor of 30-day readmission in patients with acute exacerbation ...

Acute exacerbations in chronic obstructive pulmonarydisease (COPD) and asthma are potentiallylife-threatening clinical events that may result insubstantial morbidity and mortality. Treatment ofthese ...

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Proton pump inhibitor (PPI) use in patients with chronic obstructive airway diseases is associated with an increased exacerbation risk.